Premium
ESTIMATION OF LONG‐TERM SURVIVAL WITH TAFASITAMAB + LENALIDOMIDE (LEN) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)
Author(s) -
Salles G,
Goswami B,
Bagnardi V,
Dey D,
Winderlich M,
Ambarkhane S,
Huang D,
Nowakowski G. S
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.90_2880
Subject(s) - lenalidomide , diffuse large b cell lymphoma , medicine , refractory (planetary science) , lymphoma , oncology , multiple myeloma , biology , astrobiology